Marjorie Meyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marjorie Meyer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Diantha Howard
From the Department of Obstetrics and Gynecology (MM, AB, DP), Department of Biostatisitcs (DH), and Department of Neonatal Medicine (AJ), University of Vermont, Burlington; Department of Neonatal Medicine (JM), Fletcher Allen Health Care, Burlington, Vermont; and VT AHS- Division of Alcohol and Drug Treatment Programs (TM), Burlington
3 shared publicationsAnna Benvenuto
From the Department of Obstetrics and Gynecology (MM, AB, DP), Department of Biostatisitcs (DH), and Department of Neonatal Medicine (AJ), University of Vermont, Burlington; Department of Neonatal Medicine (JM), Fletcher Allen Health Care, Burlington, Vermont; and VT AHS- Division of Alcohol and Drug Treatment Programs (TM), Burlington
2 shared publicationsDawn Plante
From the Department of Obstetrics and Gynecology (MM, AB, DP), Department of Biostatisitcs (DH), and Department of Neonatal Medicine (AJ), University of Vermont, Burlington; Department of Neonatal Medicine (JM), Fletcher Allen Health Care, Burlington, Vermont; and VT AHS- Division of Alcohol and Drug Treatment Programs (TM), Burlington
2 shared publicationsJerilyn Metayer
Department of Pediatrics, University of Vermont Medical Center, Burlington
2 shared publicationsAbigail M. Crocker
From the Department of Obstetrics, Gynecology and Reproductive Sciences (MCM), Department of Pediatrics (AMJ), Department of Mathematics and Statistics (AMC), and Departments of Psychiatry and Psychology (SHH), University of Vermont, Burlington, VT
1 shared publicationAnanda Keefer Norris
1 shared publication
Latest Publications
- 25 May 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (20) , 2119-2120
US Hospital Data About Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses
To the Editor The recent article describing neonatal abstinence syndrome (NAS) and maternal opioid-related diagnoses (MOD) from 2010 to 2017 provided interesting information.1 As obstetric and neonatal care practitioners at the only academic medical center in Vermont, we would like to highlight the findings in our state and discuss the interpretation of discharge data in this study.
- 25 May 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (20) , 2119-2120
US Hospital Data About Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses
To the Editor The recent article describing neonatal abstinence syndrome (NAS) and maternal opioid-related diagnoses (MOD) from 2010 to 2017 provided interesting information.1 As obstetric and neonatal care practitioners at the only academic medical center in Vermont, we would like to highlight the findings in our state and discuss the interpretation of discharge data in this study.
- 1 November 2015
- Published by Elsevier in Preventive Medicine
- Vol. 80, 18-22
Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas
- 1 November 2015
- Published by Elsevier in Preventive Medicine
- Vol. 80, 18-22
Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas
- 1 March 2015
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 9 (2) , 81-86
Methadone and Buprenorphine for Opioid Dependence During Pregnancy
Objectives: To compare maternal characteristics, prenatal care, and newborn outcomes in a cohort of opioid-dependent pregnant women treated with methadone versus buprenorphine. Methods: In a retrospective cohort study, 609 pregnant, opioid-dependent women were treated with methadone (n = 248) or buprenorphine (n = 361) between 2000 and 2012 at a single institution. Results: Mothers treated with buprenorphine were more likely to start medication before or earlier in pregnancy, had longer gestation, and gave birth to larger infants. Newborns of buprenorphine- versus methadone-maintained mothers required treatment for neonatal abstinence significantly less often and for a shorter duration. Conclusions: These data suggest pregnancy outcomes with buprenorphine to treat opioid dependence during pregnancy in clinical practice are as good and often better than outcomes with methadone. These results are consistent with efficacy data from randomized clinical trials and further support the use of buprenorphine for the treatment of opioid dependence during pregnancy.
- 1 March 2015
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 9 (2) , 81-86
Methadone and Buprenorphine for Opioid Dependence During Pregnancy
Objectives: To compare maternal characteristics, prenatal care, and newborn outcomes in a cohort of opioid-dependent pregnant women treated with methadone versus buprenorphine. Methods: In a retrospective cohort study, 609 pregnant, opioid-dependent women were treated with methadone (n = 248) or buprenorphine (n = 361) between 2000 and 2012 at a single institution. Results: Mothers treated with buprenorphine were more likely to start medication before or earlier in pregnancy, had longer gestation, and gave birth to larger infants. Newborns of buprenorphine- versus methadone-maintained mothers required treatment for neonatal abstinence significantly less often and for a shorter duration. Conclusions: These data suggest pregnancy outcomes with buprenorphine to treat opioid dependence during pregnancy in clinical practice are as good and often better than outcomes with methadone. These results are consistent with efficacy data from randomized clinical trials and further support the use of buprenorphine for the treatment of opioid dependence during pregnancy.
- 1 June 2014
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 41 (2) , 297-306
The Perils of Opioid Prescribing During Pregnancy
- 1 June 2014
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 41 (2) , 297-306
The Perils of Opioid Prescribing During Pregnancy
- 1 June 2012
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 6 (2) , 124-130
Development of a Substance Abuse Program for Opioid-Dependent Nonurban Pregnant Women Improves Outcome
Background: The goal of this study was to determine whether improved access to medication assisted therapy in the general population, with improved coordination of ancillary services for pregnant women, improved perinatal outcomes in a nonurban area. Methods: The cohort of women treated for opioid dependence during pregnancy with medication-assisted therapy and delivered at a single institution between 2000 and 2006 were retrospectively identified (n = 149 women; n = 151 neonates). Access to opioid agonist therapy for the general population was determined as the combined number of available treatment positions for medication-assisted therapy. Treatment during pregnancy (interim substitution therapy vs opioid treatment program) and pregnancy outcomes were noted from chart review. The primary outcome of trend of prenatal care indices and newborn birth weight over time was determined by Kendall's tau. Results: As access to treatment in the general population expanded from 2000 to 2006, the number of women receiving treatment increased, the proportion of women receiving interim substitution therapy decreased (P < 0.001), gestational age at the initiation of treatment decreased (P < 0.001), and the proportion of women receiving treatment before pregnancy increased (P < 0.001). Infants delivered to mothers in a treatment program had improved birth weight z score compared with those receiving interim substitution therapy (P = 0.007). The proportion of infants discharged to the care of the mother and remaining in maternal care at 1 year improved both over time (P = 0.03; P = 0.004) and with treatment within a treatment program (P < 0.001; P = 0.004). Conclusions: Improved access to opioid agonist treatment programs for the general population in nonurban areas improves perinatal outcome and retention of maternal guardianship.
- 1 June 2012
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 6 (2) , 124-130
Development of a Substance Abuse Program for Opioid-Dependent Nonurban Pregnant Women Improves Outcome
Background: The goal of this study was to determine whether improved access to medication assisted therapy in the general population, with improved coordination of ancillary services for pregnant women, improved perinatal outcomes in a nonurban area. Methods: The cohort of women treated for opioid dependence during pregnancy with medication-assisted therapy and delivered at a single institution between 2000 and 2006 were retrospectively identified (n = 149 women; n = 151 neonates). Access to opioid agonist therapy for the general population was determined as the combined number of available treatment positions for medication-assisted therapy. Treatment during pregnancy (interim substitution therapy vs opioid treatment program) and pregnancy outcomes were noted from chart review. The primary outcome of trend of prenatal care indices and newborn birth weight over time was determined by Kendall's tau. Results: As access to treatment in the general population expanded from 2000 to 2006, the number of women receiving treatment increased, the proportion of women receiving interim substitution therapy decreased (P < 0.001), gestational age at the initiation of treatment decreased (P < 0.001), and the proportion of women receiving treatment before pregnancy increased (P < 0.001). Infants delivered to mothers in a treatment program had improved birth weight z score compared with those receiving interim substitution therapy (P = 0.007). The proportion of infants discharged to the care of the mother and remaining in maternal care at 1 year improved both over time (P = 0.03; P = 0.004) and with treatment within a treatment program (P < 0.001; P = 0.004). Conclusions: Improved access to opioid agonist treatment programs for the general population in nonurban areas improves perinatal outcome and retention of maternal guardianship.
- 1 October 2010
- Published by Wiley in European journal of pain
- Vol. 14 (9) , 939-943
Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy
Objective: To determine whether buprenorphine maintenance alters intrapartum or postpartum pain or medication requirements.Methods: Sixty three patients treated with buprenorphine for opioid dependence during pregnancy (vaginal n = 44; cesarean n = 19) were matched retrospectively to control women. Analgesic medication and pain scores (0–10) were extracted from the medical record. Primary endpoint: opioid utilization postpartum (oxycodone equivalents). Secondary endpoints: pain scores and intrapartum analgesia.Results: There were no differences in intrapartum pain or analgesia. Following vaginal birth, buprenorphine maintained women had increased pain (buprenorphine 2.7 (1.7, 4.0); control 2.1 (1.2, 3.0), p = 0.006) but no increase in opioid utilization (buprenorphine: 11.8 ± 24.8; control 5.4 ± 10.4 mg/24 h, p = 0.10); following cesarean delivery both pain (buprenorphine: 5.1 (4.1, 6.1); control: 3.3 (2.5, 4.1), p = 0.009) and opioid utilization (buprenorphine: 89.3 ± 38.0, control: 60.9 ± 13.1 mg/24 h, p = 0.004) were increased.Conclusion: Buprenorphine maintained women have similar intrapartum pain and analgesic needs during labor, but experience more postpartum pain and require 47% more opioid analgesic following cesarean delivery.
- 1 October 2010
- Published by Wiley in European journal of pain
- Vol. 14 (9) , 939-943
Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy
Objective: To determine whether buprenorphine maintenance alters intrapartum or postpartum pain or medication requirements.Methods: Sixty three patients treated with buprenorphine for opioid dependence during pregnancy (vaginal n = 44; cesarean n = 19) were matched retrospectively to control women. Analgesic medication and pain scores (0–10) were extracted from the medical record. Primary endpoint: opioid utilization postpartum (oxycodone equivalents). Secondary endpoints: pain scores and intrapartum analgesia.Results: There were no differences in intrapartum pain or analgesia. Following vaginal birth, buprenorphine maintained women had increased pain (buprenorphine 2.7 (1.7, 4.0); control 2.1 (1.2, 3.0), p = 0.006) but no increase in opioid utilization (buprenorphine: 11.8 ± 24.8; control 5.4 ± 10.4 mg/24 h, p = 0.10); following cesarean delivery both pain (buprenorphine: 5.1 (4.1, 6.1); control: 3.3 (2.5, 4.1), p = 0.009) and opioid utilization (buprenorphine: 89.3 ± 38.0, control: 60.9 ± 13.1 mg/24 h, p = 0.004) were increased.Conclusion: Buprenorphine maintained women have similar intrapartum pain and analgesic needs during labor, but experience more postpartum pain and require 47% more opioid analgesic following cesarean delivery.
- 1 August 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (2) , 261-266
Intrapartum and Postpartum Analgesia for Women Maintained on Methadone During Pregnancy
OBJECTIVE: To determine whether methadone maintenance alters intrapartum or postpartum pain or medication requirements. METHODS: Sixty-eight patients treated with methadone for opiate dependence during pregnancy (vaginal n=35; cesarean n=33) were matched retrospectively to control women. Analgesic medication and pain scores (0–10) were extracted from the medical record. The primary endpoint was opiate use postpartum (oxycodone equivalents). The secondary endpoints were pain scores and intrapartum analgesia. RESULTS: There were no differences in intrapartum pain or analgesia. After vaginal birth, methadone-maintained women experienced increased pain (methadone, 2.7 [1.9–5.0]; control, 1.4 [0.5–3.0], P=.001) but no increase in opiate use ([mean±standard deviation] methadone 12.7±32.1; control 6.8±12.7 mg/24 h, P=.33); after cesarean delivery both pain (methadone, 5.3 [4.1–6.0]; control, 3.0 [2.2–3.9], P=.001) and opiate use (methadone, 91.6±51.8; control, 54.0±18.6 mg/24 h, P=.001) increased. CONCLUSION: Methadone-maintained women have similar analgesic needs and response during labor, but require 70% more opiate analgesic after cesarean delivery. LEVEL OF EVIDENCE: II
- 1 August 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (2) , 261-266
Intrapartum and Postpartum Analgesia for Women Maintained on Methadone During Pregnancy
OBJECTIVE: To determine whether methadone maintenance alters intrapartum or postpartum pain or medication requirements. METHODS: Sixty-eight patients treated with methadone for opiate dependence during pregnancy (vaginal n=35; cesarean n=33) were matched retrospectively to control women. Analgesic medication and pain scores (0–10) were extracted from the medical record. The primary endpoint was opiate use postpartum (oxycodone equivalents). The secondary endpoints were pain scores and intrapartum analgesia. RESULTS: There were no differences in intrapartum pain or analgesia. After vaginal birth, methadone-maintained women experienced increased pain (methadone, 2.7 [1.9–5.0]; control, 1.4 [0.5–3.0], P=.001) but no increase in opiate use ([mean±standard deviation] methadone 12.7±32.1; control 6.8±12.7 mg/24 h, P=.33); after cesarean delivery both pain (methadone, 5.3 [4.1–6.0]; control, 3.0 [2.2–3.9], P=.001) and opiate use (methadone, 91.6±51.8; control, 54.0±18.6 mg/24 h, P=.001) increased. CONCLUSION: Methadone-maintained women have similar analgesic needs and response during labor, but require 70% more opiate analgesic after cesarean delivery. LEVEL OF EVIDENCE: II